RIGEL PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $914.31M
- P/E (TTM)
- 2.9
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $78.70M | $0.88 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | During market hours | $58.80M | $0.44 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | During market hours | $69.80M | $13.54 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | During market hours | $69.50M | $1.46 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | During market hours | $101.70M | $3.28 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | $53.30M | $0.63 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | During market hours | $57.60M | $0.80 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $55.31M | $0.70 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total revenues | 2026 | $285.00M to $295.00M | Raised |
| Net product sales | 2026 | $255.00M to $265.00M | Lowered |
| Contract revenues | 2026 | $30.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Rigel Pharmaceuticals filed with the SEC
Rigel Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rigel Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rigel Provides Business Update and 2026 Outlook
Results of operations · Other events · EX-99.1 to Form 8-K
Rigel Presents Updated Data from the Ongoing
Other events · EX-99.1 to Form 8-K
Rigel Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rigel Reports Second Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Rigel Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rigel Announces Settlement Agreement Resolving
Other events · EX-99.1 to Form 8-K
Rigel Reports Fourth Quarter and Full Year 2024
Results of operations · EX-99.1 to Form 8-K
Rigel Provides Business Update and 2025 Outlook
Results of operations · Other events · EX-99.1 to Form 8-K
Rigel Highlights Initial Data from Ongoing Phase
Other events · EX-99.1 to Form 8-K
Rigel Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Rigel Announces Reverse Stock Split
Other events · EX-99.1 to Form 8-K
Rigel Reports First Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rigel Pharmaceuticals Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
Rigel Reports Third Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Rigel Reports Second Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Rigel Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rigel Reports Fourth Quarter and Full Year
Results of operations · EX-99.1 to Form 8-K
Rigel Pharmaceuticals Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult
Other events · EX-99.1 to Form 8-K
Rigel Reports Third Quarter 2022 Financial Results
Material agreement · Results of operations · Charter or bylaw amendment · EX-99.1 to Form 8-K
Rigel Announces Top-line Results from FOCUS
Other events · EX-99.1 to Form 8-K
Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback
Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Rigel Reports Second Quarter 2022 Financial
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K